|
New alliance takes aim at inconsistent biomarker interpretation across pathologists, a persistent challenge in drug development
HUNTSVILLE, Ala. and HAMBURG, Germany, March 24, 2026 /PRNewswire/ -- Inconsistent biomarker interpretation across pathologists remains one of the more stubborn challenges in clinical trial development, contributing to variability in patient stratification and eroding confidence in critical go/no-go decisions. Discovery Life Sciences (Discovery), a provider of biospecimens and biomarker specialty lab services, and Mindpeak, a leading company in AI-powered digital pathology, today announced a partnership designed to address that problem directly, integrating AI-enabled digital image analysis into pathology services for immunohistochemistry (IHC) and multiplex immunofluorescence (mIF) in global clinical trials.
The collaboration aims to support biopharma R&D and clinical research by improving biomarker quantification and inter-reader concordance, helping to reduce variability, de-risk biomarker-driven trials and strengthen confidence in critical development decisions.
The partnership couples Mindpeak's AI platform with Discovery's tissue biomarker services to analyze IHC and mIF slides. Mindpeak's technology acts as a safeguarding tool for biopharma, reducing risks in biomarker development by improving consistency in interpretation across pathologists. It includes AI-enabled pathology workflows, pathologist training via Mindpeak's peakAcademy, and AI-guided microdissection algorithms to isolate specific tissue regions with high accuracy.
Discovery brings significant clinical infrastructure to the alliance. Its Biomarker Academy, a peer-to-peer pathologist training program established in 2008, has trained more than 6,000 pathologists in biomarker interpretation and scoring over the past 15 years. Discovery has supported more than 2,000 clinical trial programs, with 350 currently active, and has completed over 35 IVDR-compliant studies across 16 EU countries involving 25 biomarkers in the past four years. This partnership extends Discovery's AI advancements, building on existing H&E-focused AI solutions for biospecimen analysis, including automated quality control, tumor quantification, and detailed tumor microenvironment characterization across various therapeutic areas.
"As AI use in pathology increases for clinical research, this partnership with Mindpeak allows integration of modeling tools that can enable improved accuracy in biomarker analysis," said Greg Herrema, CEO of Discovery Life Sciences. "Combining these AI capabilities with our clinical trials expertise will help assist in advancing the development of biomarker-focused therapies."
The Mindpeak and Discovery alliance aims to streamline trial processes and enhance data reproducibility in regulated settings, supporting more confident decisions in patient stratification and therapeutic development.
"This collaboration with Discovery Life Sciences provides access to our AI platform, training and microdissection tools, supporting researchers in IHC and mIF applications and helping to drive greater consistency and confidence in biomarker assessment," said Felix Faber, Founder and CEO of Mindpeak. Additional details on the partnership and use cases will be presented at the AACR Annual Meeting 2026. Attendees can join a flash talk at the Discovery Life Sciences exhibit from April 17-22 at the San Diego Convention Center in San Diego, California. Contact info@dls.com for more information.
About Discovery Life Sciences
Discovery Life Sciences is a global leader in biospecimens and specialty lab services, enabling the discovery and development of therapeutics and diagnostics that improve patient outcomes. Our extensive portfolio of biospecimens, cellular starting materials, and preclinical ADME-tox solutions accelerates research with reliable, high-quality products and expertise. Through our comprehensive suite of specialty lab services in genomics, proteomics, cell biology, and molecular pathology, we deliver critical data and insights for biomarker discovery and both retrospective and prospective clinical trials. With a vision to be the most trusted partner in life science research and clinical development, Discovery Life Sciences is committed to advancing life sciences and transforming lives.
Visit www.dls.com and follow us on LinkedIn for more information.
About Mindpeak
Mindpeak is the leading company in AI-powered digital pathology, bridging the gap from biomarker development to clinical diagnostics. Founded in 2018, Mindpeak's AI technology enables laboratories to extract actionable insights from H&E, IHC and mIF tissue images - ranging from subcellular biomarker quantification to predictive patient stratification. The solutions support both routine diagnostics and the translation of novel biomarkers into real-world clinical applications.
For more information, visit www.mindpeak.ai or follow us on LinkedIn.
Discovery Life Sciences Media
Todd Poley
Chief Marketing Officer
+1 256 505 1578
todd.poley@dls.com
Mindpeak Media
Tanya von Ahlefeldt
MD Health – on behalf of Mindpeak
+44 (0)7590 754906
mindpeak@mdhealthcomms.com
New alliance takes aim at inconsistent biomarker interpretation across pathologists, a persistent challenge in drug development
HUNTSVILLE, Ala. and HAMBURG, Germany, March 24, 2026 /PRNewswire/ -- Inconsistent biomarker interpretation across pathologists remains one of the more stubborn challenges in clinical trial development, contributing to variability in patient stratification and eroding confidence in critical go/no-go decisions. Discovery Life Sciences (Discovery), a provider of biospecimens and biomarker specialty lab services, and Mindpeak, a leading company in AI-powered digital pathology, today announced a partnership designed to address that problem directly, integrating AI-enabled digital image analysis into pathology services for immunohistochemistry (IHC) and multiplex immunofluorescence (mIF) in global clinical trials.
The collaboration aims to support biopharma R&D and clinical research by improving biomarker quantification and inter-reader concordance, helping to reduce variability, de-risk biomarker-driven trials and strengthen confidence in critical development decisions.
The partnership couples Mindpeak's AI platform with Discovery's tissue biomarker services to analyze IHC and mIF slides. Mindpeak's technology acts as a safeguarding tool for biopharma, reducing risks in biomarker development by improving consistency in interpretation across pathologists. It includes AI-enabled pathology workflows, pathologist training via Mindpeak's peakAcademy, and AI-guided microdissection algorithms to isolate specific tissue regions with high accuracy.
Discovery brings significant clinical infrastructure to the alliance. Its Biomarker Academy, a peer-to-peer pathologist training program established in 2008, has trained more than 6,000 pathologists in biomarker interpretation and scoring over the past 15 years. Discovery has supported more than 2,000 clinical trial programs, with 350 currently active, and has completed over 35 IVDR-compliant studies across 16 EU countries involving 25 biomarkers in the past four years. This partnership extends Discovery's AI advancements, building on existing H&E-focused AI solutions for biospecimen analysis, including automated quality control, tumor quantification, and detailed tumor microenvironment characterization across various therapeutic areas.
"As AI use in pathology increases for clinical research, this partnership with Mindpeak allows integration of modeling tools that can enable improved accuracy in biomarker analysis," said Greg Herrema, CEO of Discovery Life Sciences. "Combining these AI capabilities with our clinical trials expertise will help assist in advancing the development of biomarker-focused therapies."
The Mindpeak and Discovery alliance aims to streamline trial processes and enhance data reproducibility in regulated settings, supporting more confident decisions in patient stratification and therapeutic development.
"This collaboration with Discovery Life Sciences provides access to our AI platform, training and microdissection tools, supporting researchers in IHC and mIF applications and helping to drive greater consistency and confidence in biomarker assessment," said Felix Faber, Founder and CEO of Mindpeak. Additional details on the partnership and use cases will be presented at the AACR Annual Meeting 2026. Attendees can join a flash talk at the Discovery Life Sciences exhibit from April 17-22 at the San Diego Convention Center in San Diego, California. Contact info@dls.com for more information.
About Discovery Life Sciences
Discovery Life Sciences is a global leader in biospecimens and specialty lab services, enabling the discovery and development of therapeutics and diagnostics that improve patient outcomes. Our extensive portfolio of biospecimens, cellular starting materials, and preclinical ADME-tox solutions accelerates research with reliable, high-quality products and expertise. Through our comprehensive suite of specialty lab services in genomics, proteomics, cell biology, and molecular pathology, we deliver critical data and insights for biomarker discovery and both retrospective and prospective clinical trials. With a vision to be the most trusted partner in life science research and clinical development, Discovery Life Sciences is committed to advancing life sciences and transforming lives.
Visit www.dls.com and follow us on LinkedIn for more information.
About Mindpeak
Mindpeak is the leading company in AI-powered digital pathology, bridging the gap from biomarker development to clinical diagnostics. Founded in 2018, Mindpeak's AI technology enables laboratories to extract actionable insights from H&E, IHC and mIF tissue images - ranging from subcellular biomarker quantification to predictive patient stratification. The solutions support both routine diagnostics and the translation of novel biomarkers into real-world clinical applications.
For more information, visit www.mindpeak.ai or follow us on LinkedIn.
Discovery Life Sciences Media
Todd Poley
Chief Marketing Officer
+1 256 505 1578
todd.poley@dls.com
Mindpeak Media
Tanya von Ahlefeldt
MD Health – on behalf of Mindpeak
+44 (0)7590 754906
mindpeak@mdhealthcomms.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Discovery Life Sciences and Mindpeak Partner to Bring AI Precision to Cancer Biomarker Testing in Global Clinical Trials
79th Festival de Cannes • Spotlight on Chinese Cinema • China Pavilion
CANNES, France, May 21, 2026 /PRNewswire/ -- On May 14 (local time), the Chinese film My World Without Me, directed by Tian Hairong, was screened at the Palais des Festivals in Cannes. Selected for the International Promotional Screening Unit of the 79th Festival de Cannes, the film garnered warm applause and high praise from audiences around the world, as well as invaluable feedback and insights.
Following the screening, the film's creative team joined a themed panel at the China Pavilion titled "The Power of Images and Care for the Soul," engaging in a heartfelt dialogue with filmmakers and audiences from across the globe on the themes of life and adversity — resonating deeply with the tender hearts of people from all cultural backgrounds. The panel was hosted by China Film Foundation & China Film Association and organized by China Film Foundation • Wutianming Film Fund.
About the Film and Its Creative Team
My World Without Me is directed and headlined by Tian Hairong, with Zhang Hanyu serving as executive producer for the first time. The film was crafted over nearly seven years with exceptional care and dedication. It focuses on the contemporary community of people with hidden depression, conveying love and hope through the quiet spaces of daily life and the gentle light found in ordinary moments. Confronting suffering head-on, the film exemplifies the restrained aesthetics and humanistic warmth characteristic of Chinese realist cinema, offering an Eastern perspective on mental health narratives.
Tian Hairong is a graduate of the Performance Department of the Shanghai Theatre Academy and a renowned actress and producer in mainland China. She received the Golden Deer Award for Best Actress at the Changchun International Film Festival for Romantic Girl, the Best Actress award at the Nordic International Film Festival for The Spirit of a Generation: Tang Qunying, and the Best Supporting Actress award at the 12th Macao International Film Festival. Tian expressed her hope that through international platforms such as Cannes, the world will come to feel the warmth and depth of Chinese cinema.
International Recognition
French director Frédéric Oberlin praised the film for using a uniquely Eastern mastery of emotion to deliver silent feelings directly to the heart. Sinologist Luisa Prudentino noted after viewing the film that its sincere emotional core transcends cultural barriers, protecting the dignity of life and becoming a warm thread of empathy connecting different civilizations.
The film is set to continue participating in further international film festivals, using the power of cinema to build bridges of cultural communication and to help Chinese stories reach the world in a manner rich with humanistic care.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Touching Hearts Through Cinema -- Chinese Film "My World Without Me" Earns High Praise at Cannes
